The Centers for Medicare & Medicaid Services (CMS) has issued its calendar year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) final rule with comment period (Final Rule). The rule finalizes substantial cuts to expected hospital outpatient department payments while revising several of the proposed policies.

Overall, the Final Rule foreshadows significant changes in reimbursement associated with the provision of common outpatient services, the 340B program and significant changes to the manner in which provider-based departments are certified and recognized in the Medicare program. Attestations that historically were optional will now be mandatory. Large healthcare systems should prepare for submissions and approvals to avoid any payment and reimbursement challenges that could occur once the requirements come online in 2028.

Key takeaways

  • Off-campus departments: Beginning in 2028, each off-campus provider-based department (PBD) must have its own National Provider Identifier, distinct from the main provider’s, and a provider-based attestation on file or risk losing OPPS payment. Hospitals must prepare for these requirements during 2027.
  • 340B: CMS scaled back proposed payment reductions but finalized significant changes affecting both 340B drug reimbursement and the separate remedy for its prior 340B payment policy.
  • Site-neutral payment: Site-neutral payment reductions will expand to include certain imaging services furnished in excepted, or grandfathered, off-campus PBDs, further reducing hospital reimbursement for such services.
  • Site of service: CMS continued phasing out the inpatient-only list and substantially expanded the procedures eligible for Medicare payment when performed in ASCs.

Payment effects will vary by hospital

CMS finalized a 2.3% OPPS payment increase for hospitals meeting applicable quality reporting requirements, but after accounting for the Final Rule's payment policies and other adjustments, CMS estimates that overall OPPS payments will rise by 1.7% in CY 2027, with widely varying effects by hospital category.

CMS projects payments will rise by 5.6% for rural hospitals, 6.5% for non-teaching hospitals and 10.5% for proprietary hospitals. In contrast, it projects decreases of 2.0% for major teaching hospitals and 1.1% for government-owned hospitals.

These figures are aggregate projections, not forecasts for individual hospitals. A hospital's actual results will depend on factors such as its 340B participation and outpatient service mix.

The rate increase falls short of hospital industry expectations, adding financial pressure on safety-net institutions and other hospitals serving large uninsured populations or facing operational cuts. Hospitals contend that these modest increases fail to account for their financial challenges and growing concerns about the sustainability of independent hospitals and smaller systems.

Off-campus departments: New requirements take shape for 2028

Beginning January 1, 2028, section 6225 of the Consolidated Appropriations Act, 2026 allows OPPS payment for an off-campus PBD’s items and services only if the department bills under its own National Provider Identifier (NPI), distinct from the main provider’s, and the main provider has submitted the required provider-based attestation.

Each off-campus PBD must obtain its NPI before the initial attestation is submitted. That attestation must be filed within the two years before services are furnished, and later attestations are required at least every five years. An attestation submitted within the two years before January 1, 2028 will satisfy the requirement even if CMS has not yet issued a provider-based determination. In practice, hospitals should begin preparing for NPI enrollment and make their provider-based attestations during 2027.

The Final Rule largely adopts the proposed framework and adds key implementation details. Under the new requirements, all hospital operations at a single physical address listed in the Provider Enrollment, Chain and Ownership System (PECOS) will count as one off-campus PBD. The Final Rule also clarifies which outpatient locations are off-campus; for example, a department within 250 yards of a hospital's remote location generally will not be treated as an off-campus PBD subject to the separate NPI and attestation requirements.

CMS will also create a standardized online attestation form that hospitals will use to demonstrate compliance with provider-based requirements, replacing the current contractor-specific templates. Facilities that are not paid under the OPPS, such as critical access hospitals and rural health clinics, are not subject to the new requirements.

340B: CMS moderates proposed payment cuts

Starting in CY 2027, Medicare will generally pay for separately payable drugs acquired through the 340B Drug Pricing Program at average sales price (ASP) minus 28%, down from ASP plus 6%. Although substantial, the cut is smaller than the ASP minus 33.4% rate CMS proposed in this summer’s CY 2027 proposed rule.

The lower rate generally applies to OPPS hospitals except rural sole community hospitals, PPS-exempt cancer hospitals and children's hospitals. Critical access hospitals and rural emergency hospitals are unaffected because they are not paid under the OPPS. The policy also applies to 340B-acquired drugs furnished in non-excepted off-campus PBDs. Beginning January 1, 2027, hospitals must use the applicable drug claim modifiers: JG for 340B-acquired drugs subject to the adjustment, TB for exempt 340B-acquired drugs and ND for separately payable drugs not acquired through 340B.

The policy applies to separately payable drugs, biologicals, biosimilars and radiopharmaceuticals acquired through the 340B program, subject to the applicable pricing methodology. Where ASP is unavailable, CMS finalized alternative pricing rules. Products paid using mean unit cost or invoice pricing are not subject to the additional reduction. It does not apply to vaccines, drugs with transitional pass-through status, qualifying non-opioid pain management drugs or drugs covered as preventive services, such as HIV pre-exposure prophylaxis. Certain separately payable cell and gene therapies acquired through the 340B program may become subject to the lower 340B rate after their transitional pass-through status expires, with the applicable rate taking effect the following quarter.

CMS's OPPS impact model estimates approximately US$4.65 billion in reduced payments for separately payable 340B-acquired drugs, including beneficiary copayments, with an equal aggregate redistribution through a 7.5% increase in payment rates for non-drug OPPS items and services. CMS acknowledged that some hospitals may lose more in 340B drug payments than they gain through the corresponding increase in payments for non-drug services. Separately, CMS estimates US$640 million in Medicare savings and US$160 million in reduced beneficiary copayments from applying the policy to non-excepted off-campus PBDs. CMS estimates total beneficiary drug copayment reductions of approximately US$1.1 billion, including the US$160 million associated with non-excepted departments. Lower drug copayments do not necessarily translate into net beneficiary savings across all outpatient services because the redistribution increases payments, and associated cost sharing, for non-drug services.

CMS selected the ASP minus 28% alternative based on Health Resources and Services Administration (HRSA) 340B ceiling price data, rather than the ASP minus 33.4% rate derived directly from its 2026 acquisition cost survey. CMS maintains that the statute requires it to take survey data into account, not to use those data exclusively to calculate payment rates, and that the survey validates the ceiling-price approach. The methodology could face legal challenges concerning the survey's adequacy and CMS's reliance on ceiling prices. As the Final Rule recounts, the Supreme Court's 2022 decision in American Hospital Association v. Becerra barred hospital-group payment variations in the absence of the required acquisition cost survey. Unlike the earlier policy, the CY 2027 policy follows a completed survey; the prior decision does not itself resolve the validity of the new methodology.

340B remedy: CMS accelerates recovery of prior payments

The Becerra decision also led to a separate remedy for CMS's CY 2018-2022 340B payment policy. Under the remedy, CMS made one-time lump-sum payments to affected 340B hospitals in early 2024 to address prior drug underpayments and set up a separate process to recover about US$7.8 billion in additional payments hospitals had received for non-drug services under the earlier policy.

CMS began recovering the approximately US$7.8 billion in CY 2026 through a 0.5% reduction to the OPPS conversion factor for non-drug items and services, which would have continued until roughly CY 2041. CMS proposed a steeper 3% reduction starting in CY 2027, but the Final Rule instead adopts a 2% annual reduction, with full recovery now expected in CY 2031 and a smaller final-year offset anticipated to avoid exceeding the approximately US$7.8 billion target. CMS projects the offset will reduce payments to affected hospitals by approximately US$1.6 billion in CY 2027. The offset applies to affected 340B and non-340B hospitals, not only to hospitals that received drug remedy payments. Hospitals with a CMS certification number effective date on January 2, 2018 or later are exempt.

Site-neutral payment expands to imaging

CMS finalized its proposal to extend site-neutral payment for imaging services without contrast furnished in excepted, or "grandfathered," off-campus PBDs. Starting in CY 2027, and with limited exceptions, Medicare will pay 40% of the OPPS rate for these services under section 1833(t)(2)(F) of the Social Security Act. Affected services include certain bone density scans, x-rays, ultrasounds, CT scans and MRIs. CMS already uses this methodology for clinic visits and drug administration services in these departments, and finalizing the policy continues the agency’s longstanding efforts to promote site-neutrality in Medicare payments. Rural sole community hospitals are exempt from the policy.

These payment reductions will not be redirected to other OPPS services. CMS estimates the change will lower Medicare Part B spending by about US$260 million and beneficiary cost-sharing by about US$70 million in CY 2027, with projected savings of more than US$9 billion from CY 2027 through CY 2036.

IPO phase-out expands outpatient and ASC options

CMS started a three-year phase-out of the inpatient-only (IPO) list in CY 2026. Removing a procedure from the list does not require it to be performed in the outpatient setting. It allows Medicare to pay for the procedure in an outpatient setting there when its performance in an outpatient setting is clinically appropriate.

In CY 2027, CMS will remove 637 additional services from the IPO list. The remaining services are expected to be considered during the final phase of the policy in CY 2028.

The Final Rule also adds 618 procedures to the ASC Covered Procedures List. These additions will provide hospitals, ASCs and physicians with greater flexibility in choosing where to perform affected procedures when clinically appropriate.

Looking ahead

With most provisions taking effect January 1, 2027, hospitals and health systems will need to assess the combined financial effect of the 340B drug payment reductions, changes in payments for non-drug services, accelerated 340B remedy recoupment, and reductions in payment associated with application of the site-neutral imaging payment on their healthcare system budgets to reevaluate service and capital expenditures in the coming year.

The Final Rule's effects extend beyond 2027. Hospitals with off-campus provider-based operations should begin preparing now for the separate NPI and attestation requirements that take effect in 2028. Organizations should also watch for potential legal challenges to the new 340B payment methodology, the January 4, 2027 comment deadline, and future CMS rulemaking.

Norton Rose Fulbright’s healthcare team advises hospitals and health systems on the financial, operational and regulatory implications of Medicare payment policies. Our team can help clients assess the impact of the Final Rule, navigate implementation and compliance issues, and address disputes or litigation that may arise as the new policies take effect.

Contact